External validation of the NADIR model for early prostate‐specific antigen response prediction in enzalutamide‐treated metastatic hormone‐sensitive prostate cancer: An analysis of the ARCHES trial
Cancer · 01.10.2026 · 132 (19)
DOI: 10.1002/cncr.70615 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Cancer, online erschienen am 25.09.2026. Verfasst von Soumyajit Roy und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Clev…. Hauptthemen laut MEDLINE: Phenylthiohydantoin, Prostate-Specific Antigen, Prostatic Neoplasms. Die Arbeit nennt 15 Literaturangaben. Gefördert von: Prostate Cancer Foundation.
Abstract (Originalsprache)
Background
Early favorable prostate‐specific antigen (PSA) response to ≤0.2 ng/mL by 6 months is associated with superior overall survival (OS) in metastatic hormone‐sensitive prostate cancer (mHSPC). The nadir androgen receptor pathway inhibitor (ARPI)‐derived integrative response (NADIR) model is a multivariable model developed to predict this early favorable PSA response in patients receiving ARPI. The authors report an independent external validation of the locked NADIR model in the ARCHES trial.
Methods
Of 574 enzalutamide‐treated patients, 558 with complete predictors were included. Discrimination, Brier score/index of prediction accuracy (IPA), and calibration were assessed. Predicted probability tertiles were used descriptively for PSA response. Six‐month landmark Cox models explored associations with OS. A sensitivity analysis restricted the cohort to
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA.
- Duke University Medical Center, Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina, USA.
- Huntsman Cancer Institute (NCI-CCC), University of Utah, Salt Lake City, Utah, USA.
- UC San Diego Moores Cancer Center, La Jolla, California, USA.
- Division of Solid Tumor Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA.
- Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
ORCID-Profile: Soumyajit Roy, Andrew J Armstrong, Rana R McKay, Jason R Brown, Scott C Morgan, Christopher J D Wallis, Daniel E Spratt
Förderung
- Prostate Cancer Foundation
Zitieren
APA
Roy, S., Armstrong, A. J., Agarwal, N., McKay, R. R., Jia, A. Y., Lichtman-Mikol, S., Barata, P. C., Garcia, J. A., Brown, J. R., Mumgandi, Y., Basourakos, S. P., Sheng, I. Y., Kishan, A. U., Zaorsky, N. G., Shoag, J. E., Morgan, S. C., Wallis, C. J. D., Sun, Y., Small, E. J., …, & Spratt, D. E. (2026). External validation of the NADIR model for early prostate‐specific antigen response prediction in enzalutamide‐treated metastatic hormone‐sensitive prostate cancer: An analysis of the ARCHES trial. Cancer, 132(19). https://doi.org/10.1002/cncr.70615
Vancouver
Roy S, Armstrong AJ, Agarwal N, McKay RR, Jia AY, Lichtman-Mikol S, et al. External validation of the NADIR model for early prostate‐specific antigen response prediction in enzalutamide‐treated metastatic hormone‐sensitive prostate cancer: An analysis of the ARCHES trial. Cancer. 2026;132(19). doi:10.1002/cncr.70615
BibTeX
@article{Roy2026,
author = {Roy, Soumyajit and Armstrong, Andrew J and Agarwal, Neeraj and McKay, Rana R and Jia, Angela Y and Lichtman-Mikol, Samuel and Barata, Pedro C and Garcia, Jorge A and Brown, Jason R and Mumgandi, Yashasvi and Basourakos, Spyridon P and Sheng, Iris Y and Kishan, Amar U and Zaorsky, Nicholas G and Shoag, Jonathan E and Morgan, Scott C and Wallis, Christopher J D and Sun, Yilun and Small, Eric J and Saad, Fred and Shore, Neal D and Spratt, Daniel E},
title = {External validation of the NADIR model for early prostate‐specific antigen response prediction in enzalutamide‐treated metastatic hormone‐sensitive prostate cancer: An analysis of the ARCHES trial},
journal = {Cancer},
year = {2026},
volume = {132},
number = {19},
doi = {10.1002/cncr.70615}
}
EUVIMED